1. Scrip
  2. >>Business
  3. >>Deals

BMS/Celgene Post-Merger Early R&D Strategy: Partnerships Are Still Key, Vessey Says

 
• By Mandy Jackson

Research and early development head Rupert Vessey, who had a similar role at Celgene, told Scrip that integration of the company’s pipeline into Bristol is nearly complete with few overlapping programs.

Bristol’s Rupert Vessey
Bristol's Rupert Vessey said deal-making will continue after the Celgene merger • Source: Bristol-Myers Squibb Co.

The integration of Celgene Corp.’s research, discovery, preclinical and early clinical development programs into Bristol-Myers Squibb Co.’s R&D pipeline is almost complete, but the combined company still is looking to add new drug candidates and technologies from external partners, Bristol’s Rupert Vessey, executive vice president of research and early development, told Scrip in a recent interview.

Vessey, who had a similar role at Celgene before the companies completed their $76bn merger, said on the sidelines of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Top 10 Drugs Q1 2025: Keytruda Dominates; Mounjaro Climbs

 
• By Eleanor Malone

Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.